Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation
A Miller, S Shapiro, R Gershtein, A Kinarty… - Journal of …, 1998 - Elsevier
The synthetic polypeptide copolymer-1 (Cop-1; Copaxone®; Glatiramer Acetate) has been
recently approved as an effective treatment in relapsing multiple sclerosis (MS). A large
body of evidence demonstrates that Cop-1 induces active suppression of CNS-inflammatory
disease in animal models. However, Cop-1-mediated suppressor mechanisms have not yet
been elucidated in humans. A 12-month open study following clinical and immunological
parameters of ten relapsing MS patients treated with Cop-1 is presented. Relapse rates and …
recently approved as an effective treatment in relapsing multiple sclerosis (MS). A large
body of evidence demonstrates that Cop-1 induces active suppression of CNS-inflammatory
disease in animal models. However, Cop-1-mediated suppressor mechanisms have not yet
been elucidated in humans. A 12-month open study following clinical and immunological
parameters of ten relapsing MS patients treated with Cop-1 is presented. Relapse rates and …